Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's Yim Hopes To See European-Like Robustness For US Biosimilars Market In 10 Years

Jan 30 2020

• By Michael Cipriano

FDAEntrance_1200x675

Related Content

Decade In Review: Biopharma's Shifting Legal Landscape

Jan 16 2020

FDA Biosimilars Chief Leah Christl Joining Amgen; Agency Veteran Sarah Yim Takes Her Place

Feb 03 2019

Countdown To Transition: US FDA Says 91 Drugs Will Become Biologics In March 2020

Sep 27 2019

US FDA's Stein: 'Cognitive Dissonance' Exists Between Review Divisions In Regulation Of Biosimilars

Nov 20 2019

Avoiding ‘Groundhog Day’: US FDA’s Biosimilar Action Plan Applies Lessons From Generic Competition

Jul 23 2018

Related Companies

Amgen, Inc.

AbbVie Inc.

Additional Topics

United States Leadership Biosimilars Regulation BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window